foryourhealth111-pixel/Vibe-Skills / bundled/skills/clinical-decision-support
clinical-decision-support
VerifiedGenerate professional clinical decision support (CDS) documents for pharmaceutical and clinical research settings, including patient cohort analyses (biomarker-stratified with outcomes) and treatment recommendation reports (evidence-based guidelines with decision algorithms). Supports GRADE evidence grading, statistical analysis (hazard ratios, survival curves, waterfall plots), biomarker integration, and regulatory compliance. Outputs publication-ready LaTeX/PDF format optimized for drug development, clinical research, and evidence synthesis.
| File | Kind | Size |
|---|---|---|
| README.md | markdown | 4.9 KB |
| SKILL.md | skill md | 25.6 KB |
| assets/biomarker_report_template.tex | other | 13.0 KB |
| assets/clinical_pathway_template.tex | other | 8.1 KB |
| assets/cohort_analysis_template.tex | other | 12.3 KB |
| assets/color_schemes.tex | other | 6.9 KB |
| assets/example_gbm_cohort.md | markdown | 9.1 KB |
| assets/recommendation_strength_guide.md | markdown | 11.1 KB |
| assets/treatment_recommendation_template.tex | other | 18.4 KB |
| references/biomarker_classification.md | markdown | 28.6 KB |
| references/clinical_decision_algorithms.md | markdown | 20.9 KB |
| references/evidence_synthesis.md | markdown | 32.6 KB |
| references/outcome_analysis.md | markdown | 24.1 KB |
| references/patient_cohort_analysis.md | markdown | 16.2 KB |
| references/treatment_recommendations.md | markdown | 19.2 KB |
| scripts/biomarker_classifier.py | script | 13.0 KB |
| scripts/build_decision_tree.py | script | 15.5 KB |
| scripts/create_cohort_tables.py | script | 17.6 KB |
| scripts/generate_survival_analysis.py | script | 14.9 KB |
| scripts/validate_cds_document.py | script | 12.4 KB |
assets/recommendation_strength_guide.md
View on GitHub# Recommendation Strength Guide
## GRADE Framework for Clinical Recommendations
### Components of a Recommendation
Every clinical recommendation should address:
1. **Population**: Who should receive the intervention?
2. **Intervention**: What specific treatment/action?
3. **Comparator**: Compared to what alternative?
4. **Outcome**: What are the expected results?
5. **Strength**: How strong is the recommendation?
6. **Quality of Evidence**: How confident are we in the evidence?
### Recommendation Strength (Grade 1 vs Grade 2)
#### Strong Recommendation (Grade 1)
**When to Use**:
- Desirable effects clearly outweigh undesirable effects (or vice versa)
- High or moderate quality evidence
- Values and preferences: Little variability expected
- Resource implications: Cost-effective or cost considerations minor
**Wording**: "We recommend..." or "Clinicians should..."
**Implications**:
- Most patients should receive the recommended intervention
- Adherence to recommendation could be a quality indicator
- Policy-makers can adapt as performance measure
**Examples**:
```
STRONG RECOMMENDATION FOR (Grade 1):
"We recommend osimertinib 80 mg daily as first-line therapy for adults with
advanced NSCLC harboring EGFR exon 19 deletion or L858R mutation (Strong
recommendation, High-quality evidence - GRADE 1A)."
Rationale:
- Large PFS benefit: 18.9 vs 10.2 months (HR 0.46, p<0.001)
- OS benefit: 38.6 vs 31.8 months (HR 0.80, p=0.046)
- Better tolerability: Lower grade 3-4 AEs
- Evidence: High-quality (large RCT, low risk of bias)
- Benefits clearly outweigh harms
```
```
STRONG RECOMMENDATION AGAINST (Grade 1):
"We recommend against using bevacizumab in the first-line treatment of newly
diagnosed glioblastoma to improve overall survival (Strong recommendation against,
High-quality evidence - GRADE 1A)."
Rationale:
- No OS benefit: HR 0.88 (0.76-1.02), p=0.10 (AVAglio trial)
- Toxicity: Increased grade ≥3 AEs (66% vs 52%)
- Evidence: High-quality (two large phase 3 RCTs)
- Harms outweigh lack of survival benefit
```
#### Conditional/Weak Recommendation (Grade 2)
**When to Use**:
- Desirable and undesirable effects closely balanced
- Low or very low quality evidence
- Values and preferences: Substantial variability
- Resource implications: High cost or limited access
**Wording**: "We suggest..." or "Clinicians might..."
**Implications**:
- Different choices will be appropriate for different patients
- Shared decision-making essential
- Policy-making requires substantial debate and stakeholder involvement
**Examples**:
```
CONDITIONAL RECOMMENDATION FOR (Grade 2):
"We suggest considering maintenance pemetrexed after first-line platinum-pemetrexed
chemotherapy for advanced non-squamous NSCLC in patients without disease progression
(Conditional recommendation, Moderate-quality evidence - GRADE 2B)."
Rationale:
- Modest PFS benefit: 4.0 vs 2.0 months (HR 0.62)
- No OS benefit: 13.9 vs 11.0 months (HR 0.79, p=0.23)
- Toxicity: Continued chemotherapy burden
- Quality of life: Trade-off between symptom control and treatment side effects
- Patient values: Some prioritize time off treatment, others prioritize disease control
- Shared decision-making essential
```
```
CONDITIONAL RECOMMENDATION - EITHER OPTION ACCEPTABLE (Grade 2):
"We suggest either pembrolizumab monotherapy OR pembrolizumab plus platinum-doublet
chemotherapy as first-line treatment for PD-L1 ≥50% NSCLC, based on patient
preferences and clinical factors (Conditional recommendation, High-quality evidence -
GRADE 2A)."
Rationale:
- Both regimens NCCN Category 1 preferred
- Monotherapy: Less toxicity, oral vs IV, better quality of life
- Combination: Higher ORR (48% vs 39%), numerically longer PFS
- OS: Similar between strategies
- Patient values: Varies widely (tolerability vs response rate priority)
```
### Evidence Quality (⊕⊕⊕⊕ to ⊕○○○)
#### High Quality (⊕⊕⊕⊕)
- Further research very unlikely to change confidence in effect estimate
- Consistent results from well-designed RCTs
- No serious limitations
- Direct evidence (target population, intervention, outcomes)
- Precise estimate (narrow CI)
**Example**: FLAURA trial for osimertinib in EGFR+ NSCLC - Large RCT, consistent results, low risk of bias, direct outcomes
#### Moderate Quality (⊕⊕⊕○)
- Further research likely to impact confidence and may change estimate
- RCTs with some limitations OR very strong evidence from observational studies
- Some inconsistency, indirectness, imprecision, or publication bias
**Example**: Single RCT with some limitations, or multiple RCTs with moderate heterogeneity
#### Low Quality (⊕⊕○○)
- Further research very likely to have important impact on confidence in estimate
- Observational studies OR RCTs with serious limitations
- Serious issues with consistency, directness, precision, or bias
**Example**: Well-conducted cohort study, or RCT with high attrition and unclear allocation concealment
#### Very Low Quality (⊕○○○)
- Estimate of effect very uncertain
- Case series, expert opinion, mechanistic reasoning
- Very serious limitations
**Example**: Retrospective case series, expert consensus without systematic review
## Combining Strength and Quality
### All Nine Possible Combinations
| Evidence Quality | Strong For (↑↑) | Weak For (↑) | Strong Against (↓↓) | Weak Against (↓) |
|-----------------|----------------|--------------|---------------------|------------------|
| **High (⊕⊕⊕⊕)** | Grade 1A | Grade 2A | Grade 1A (against) | Grade 2A (against) |
| **Moderate (⊕⊕⊕○)** | Grade 1B | Grade 2B | Grade 1B (against) | Grade 2B (against) |
| **Low (⊕⊕○○)** | Grade 1C* | Grade 2C | Grade 1C (against)* | Grade 2C (against) |
| **Very Low (⊕○○○)** | Grade 1D* | Grade 2D | Grade 1D (against)* | Grade 2D (against) |
*Rare: Strong recommendations usually require at least moderate-quality evidence
### Unusual Combinations (When They Occur)
**Strong Recommendation with Low Quality Evidence (Grade 1C)**
Rare, but can occur when:
- Large magnitude of effect from observational data (RR >5 or <0.2)
- Low quality evidence, but clear benefit-harm balance
- Example: Anticoagulation for atrial fibrillation (before RCTs, strong observational data)
**Weak Recommendation with High Quality Evidence (Grade 2A)**
Occurs when:
- Benefits and harms closely balanced
- Patient values highly variable
- Example: Aspirin for primary prevention in low-risk individuals (benefits small, bleeding risk present, patient values vary)
## Wording Templates
### Strong Recommendations
**FOR (↑↑)**:
- "We recommend [intervention] for [population]."
- "Clinicians should [action]."
- "[Intervention] is recommended."
**AGAINST (↓↓)**:
- "We recommend against [intervention] for [population]."
- "Clinicians should not [action]."
- "[Intervention] is not recommended."
### Conditional/Weak Recommendations
**FOR (↑)**:
- "We suggest [intervention] for [population]."
- "Clinicians might consider [action]."
- "[Intervention] may be considered for selected patients."
**AGAINST (↓)**:
- "We suggest not using [intervention] for [population]."
- "Clinicians might avoid [action]."
- "[Intervention] is generally not recommended."
**EITHER ACCEPTABLE**:
- "We suggest either [option A] or [option B] based on patient preferences."
- "Either approach is reasonable."
## Color Coding for Visual Documents
**Strong Recommendations (Green Background)**:
- RGB(0, 153, 76) or #009954
- Clear visual priority
- Use for Grade 1A, 1B
**Conditional Recommendations (Yellow Background)**:
- RGB(255, 193, 7) or #FFC107
- Indicates discussion needed
- Use for Grade 2A, 2B, 2C
**Research/Investigational (Blue Background)**:
- RGB(33, 150, 243) or #2196F3
- Clinical trial consideration
- Insufficient evidence for standard care
**Not Recommended (Red Border/Background)**:
- RGB(220, 20, 60) or #DC143C
- Strong recommendation against
- Evidence of harm or no benefit
## Common Scenarios
### Scenario 1: Strong Evidence, Clear Benefit-Harm Balance
**Example**: Pembrolizumab for PD-L1 ≥50% NSCLC
- Evidence: Large phase 3 RCT (KEYNOTE-024), n=305, well-designed
- Results: PFS HR 0.50 (0.37-0.68), OS HR 0.60 (0.41-0.89)
- Toxicity: Lower grade 3-5 AEs than chemotherapy (27% vs 53%)
- Patient values: Most prioritize efficacy and tolerability
**Recommendation**: STRONG FOR (Grade 1A)
### Scenario 2: Moderate Evidence, Balanced Trade-Offs
**Example**: Adjuvant immunotherapy for resected melanoma
- Evidence: RCT showing relapse-free survival benefit, OS data immature
- Results: Recurrence risk reduced but ongoing toxicity
- Toxicity: Immune-related AEs requiring steroids (some severe)
- Cost: High annual cost for 12 months treatment
- Patient values: Variable (some prioritize recurrence prevention, others avoid toxicity)
**Recommendation**: CONDITIONAL FOR (Grade 2B)
### Scenario 3: Low Evidence, but Severe Consequence
**Example**: Anticoagulation for prosthetic heart valve
- Evidence: No RCTs (would be unethical), observational data and mechanistic reasoning
- Consequence: Very high thromboembolic risk without anticoagulation
- Benefit-harm: Clear despite low quality evidence
**Recommendation**: STRONG FOR (Grade 1C)
### Scenario 4: High Evidence, but Patient Preferences Vary
**Example**: Breast reconstruction after mastectomy
- Evidence: High-quality data on outcomes and satisfaction
- Trade-offs: Cosmetic benefit vs additional surgery, recovery time
- Values: Highly personal decision, wide preference variability
**Recommendation**: CONDITIONAL (Grade 2A) - discuss options, patient decides
## Documentation Template
```
RECOMMENDATION: [State recommendation clearly]
Strength: [STRONG / CONDITIONAL]
Quality of Evidence: [HIGH / MODERATE / LOW / VERY LOW]
GRADE: [1A / 1B / 2A / 2B / 2C]
Evidence Summary:
- Primary study: [Citation]
- Design: [RCT / Observational / Meta-analysis]
- Sample size: n = [X]
- Results: [Primary outcome with effect size, CI, p-value]
- Quality assessment: [Strengths and limitations]
Benefits:
- [Quantified benefit 1]
- [Quantified benefit 2]
Harms:
- [Quantified harm 1]
- [Quantified harm 2]
Balance: [Benefits clearly outweigh harms / Close balance requiring discussion / etc.]
Values and Preferences: [Little variability / Substantial variability]
Cost Considerations: [If relevant]
Guideline Concordance:
- NCCN: [Category and recommendation]
- ASCO: [Recommendation]
- ESMO: [Grade and recommendation]
```
## Quality Checklist
Before finalizing recommendations, verify:
- [ ] Recommendation statement is clear and actionable
- [ ] Strength is explicitly stated (strong vs conditional)
- [ ] Quality of evidence is graded (high/moderate/low/very low)
- [ ] GRADE notation provided (1A, 1B, 2A, 2B, 2C)
- [ ] Evidence is cited with specific study results
- [ ] Benefits are quantified (effect sizes with CIs)
- [ ] Harms are quantified (AE rates)
- [ ] Balance of benefits/harms is explained
- [ ] Patient values consideration is addressed (if conditional)
- [ ] Alternative options are mentioned
- [ ] Guideline concordance is documented
- [ ] Special populations are addressed (elderly, renal/hepatic impairment)
- [ ] Monitoring requirements are specified
Related skills
| Skill | Stars | Updated | Works with | Status | Install |
|---|---|---|---|---|---|
| canvas-designanthropics/skillsCreate beautiful visual art in .png and .pdf documents using design philosophy. You should use this skill when the user asks to create a poster, piece of art, design, or other static piece. Create original visual designs, never copying existing artists' work to avoid copyright violations. | Stars: 198k | Updated | Claude CodeCodex | Verified | Install |
| docxanthropics/skillsUse this skill whenever the user wants to create, read, edit, or manipulate Word documents (.docx files) or Word templates (.dotx files). Triggers include: any mention of 'Word doc', 'word document', '.docx', '.dotx', or requests to produce professional documents with formatting like tables of contents, headings, page numbers, or letterheads. Also use when extracting or reorganizing content from .docx or .dotx files, inserting or replacing images in documents, performing find-and-replace in Word files, working with tracked changes or comments, or converting content into a polished Word document. If the user asks for a 'report', 'memo', 'letter', 'template', or similar deliverable as a Word or .docx file, use this skill. Do NOT use for PDFs, spreadsheets, Google Docs, or general coding tasks unrelated to document generation. | Stars: 198k | Updated | Claude CodeCodex | Verified | Install |
| pdfanthropics/skillsUse this skill whenever the user wants to do anything with PDF files. This includes reading or extracting text/tables from PDFs, combining or merging multiple PDFs into one, splitting PDFs apart, rotating pages, adding watermarks, creating new PDFs, filling PDF forms, encrypting/decrypting PDFs, extracting images, and OCR on scanned PDFs to make them searchable. If the user mentions a .pdf file or asks to produce one, use this skill. | Stars: 198k | Updated | Claude CodeCodex | Verified | Install |
| pptxanthropics/skillsUse this skill any time a .pptx or .potx file is involved in any way — as input, output, or both. This includes: creating slide decks, pitch decks, or presentations; reading, parsing, or extracting text from any .pptx or .potx file (even if the extracted content will be used elsewhere, like in an email or summary); editing, modifying, or updating existing presentations; combining or splitting slide files; working with templates (.potx), layouts, speaker notes, or comments. Trigger whenever the user mentions "deck," "slides," "presentation," or references a .pptx or .potx filename, regardless of what they plan to do with the content afterward. If a .pptx or .potx file needs to be opened, created, or touched, use this skill. | Stars: 198k | Updated | Claude CodeCodex | Verified | Install |